ClinicalTrials.gg
CompletedNCT07083193Updated Oct 28, 2026

A Study of AC-101 Tablets in Participants With Moderate to Severe Active Ulcerative Colitis

A Phase 1/2 interventional study of AC-101 in Ulcerative Colitis, sponsored by Accro Bioscience (Suzhou) Limited. Completed at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-28.

Sponsored by Accro Bioscience (Suzhou) Limited · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 5 months after the study started (first participant enrolled Jan 2025, registered Jul 2025).
Updated Oct 28, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
25
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 184 studies in Colitis, Ulcerative with a site in China — 73 open to participants now, 96 under way, 25 of them phase 3. Colitis, Ulcerative · China.

Enrollment
124th of 136
25 · median 121
Started
2025
with 29 others
Phase 1/2
7 of 184
2 open now
Registered
130th of 184
by date

Among the 184 studies in Colitis, Ulcerative with a site in China, this one is the 124th largest by enrollment of the 136 interventional ones that give a count, is one of 30 that started in 2025, is one of 7 in phase 1/2, and was the 130th registered.

Colitis, Ulcerative

1,857 studies on the registry are indexed under Colitis, Ulcerative; 472 are open to participants now.

Browse Colitis, Ulcerative studies →

Open to participants now

73 of the 184 studies in Colitis, Ulcerative with a site in China are open now. Recruiting first, the newest first:

68 more — sign in →

All 73 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 305 Colitis, Ulcerative studies recruiting now, 135 (44%) set no upper age limit and 134 (44%) stop at 75 or younger; 70 take children under 18; 41 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 184 studies in Colitis, Ulcerative with a site in China, or all of them as a file.
02

Study summary

The purpose of the study is to evaluate the safety, efficacy, and pharmacokinetics of AC-101 tablets in participants with moderate-to-severe ulcerative colitis.

The total study duration is up to 17 weeks, including 4-week screening, 12-week treatment period, and 1-week safety follow-up.

The study will enroll approximately 24 participants with moderate to severe active ulcerative colitis.

03

Conditions studied

  • Ulcerative Colitis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of Ulcerative Colitis (UC) or suspected UC symptom for at least 3 months prior to enrolment and confirmed diagnosis of UC by endoscopic and histopathological examinations during screening.
  • Evidence of active UC defined by modified Mayo score of 5 to 9 points (inclusive) with 3 subscores meeting the followings:

    1. Stool frequency (SF) subscore of .≥ 2 points, and
    2. Rectal bleeding (RB) subscore of .≥ 1 points, and
    3. Endoscopic (ES) subscore of ≥ 2 points (excluding friability), confirmed by screening endoscopy
  • Disease extension of ≥ 15cm from anal verge, confirmed by screening endoscopy
  • Currently using concomitant 5-salicylates (5-ASA) or oral (≤ 20 mg prednisone or equivalent, ≤ 9 mg budesonide MMX or equivalent) should keep stable doses from 2 weeks prior to enrolment till study completion.
  • Biologic-naïve or previous biological treatment for more than 5 half-lives.

Exclusion criteria

Exclusion Criteria:

  • Previous/current documented diagnosis of Crohn's Disease (CD), indeterminate colitis, severe UC required hospitalization or pulse therapy, ulcerative proctitis, fulminant colitis, ischemic colitis and other intestinal diseases.
  • Previous received 2 or more types of advanced treatment including biologics (e.g., TNF-α antibodies, IL-12/23 antibodies, integrin-α4β7 antibodies) and small molecule (e.g., JAK inhibitors, S1P receptor modulator), and all deemed by investigator as treatment failure.
  • Intravenous/rectal administration of steroids or topical administration of 5-ASA within 2 weeks prior to enrolment; systemic administration of small molecule (e.g., Tofacitinib, Upadacitinib, Ozanimod) within 4 weeks prior to enrolment.
  • Clostridium difficile infection or other enteric pathogen infection within 30 days prior to endoscopy, or positive for Clostridium difficile or other enteric pathogens prior to enrolment.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
25 participants (actual)

Study arms

  • Experimental
    AC-101 Dose 1

    Participants will receive AC-101 Dose 1 as tablets orally twice daily from Week 0 through W12

    Drug: AC-101

  • Experimental
    AC-101 Dose 2

    Participants will receive AC-101 Dose 2 as tablets orally once daily from Week 0 through W12

    Drug: AC-101

Interventions

  • DrugAC-101

    AC-101 tablets will be administered orally.

06

What researchers measure

Primary outcomes

  1. Incidence and Severity of Adverse Events

    An Adverse Event (AE) is defined as any new untoward medical condition or worsening of a pre-existing medical condition following or during exposure to an investigation product, whether or not considered causally related to the product.

    Time frame: Up to Week 13

Secondary outcomes

  1. Proportion of Participants Achieved Clinical Response

    Clinical response is defined as achieving the following changes in the modified Mayo score (excludes the physicians' global assessment) 1. A decrease from baseline in modified Mayo score of ≥ 2 points, and 2. A decrease from baseline in modified Mayo score of ≥ 30%, and 3. A decrease from baseline in rectal bleeding (RB) subscore of ≥ 1 point or absolute RB subscore ≤ 1 point The modified Mayo score is a sum of the following 3 subscores: 1. Stool frequency (SF) subscore (0-3) 2. Rectal bleeding (RB) subscore (0-3) 3. Endoscopic (ES) subscore (0-3)

    Time frame: Week 12

  2. Proportion of Participants achieved Clinical Remission

    Clinical remission is defined as achieving the following changes in the modified Mayo score 1. Absolute modified Mayo score ≤ 2 points, and 2. Absolute SF subscore ≤ 1 point, and 3. Absolute RB subscore = 0 point, and 4. Absolute ES subscore ≤ 1 point

    Time frame: Week 12

07

Study locations

1 site
  • The First Affiliated Hospital,Sun Yat-sen University
    Guangzhou, Guangdong 510080, China
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Jan 2025 to primary completion in Apr 2026, 15 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 28, 2026: primary completion Sep 2026 → Apr 2026 and completion Apr 2027 → Apr 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 16, 2025
First posted
Jul 24, 2025
StartActual
Jan 20, 2025
Primary completionActual
Apr 20, 2026was Sep 2026
CompletionActual
Apr 20, 2026was Apr 2027
Last update
Oct 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Oct 28, 2026
Primary completion
Sep 30, 2026→Apr 20, 2026 (actual)
Oct 28, 2026
Study completion
Apr 30, 2027→Apr 20, 2026 (actual)
Oct 28, 2026
Enrollment
24 (estimated)→25 (actual)
Oct 28, 2026
Show all 1 update
  1. Oct 28, 2026
    Recruiting→Completed
    Primary completion Sep 30, 2026→Apr 20, 2026 (now actual)
    Study completion Apr 30, 2027→Apr 20, 2026 (now actual)
    Enrollment 24 (estimated)→25 (actual)
    + 3 other changes: verification date, site details and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07083193
Lead sponsor
Accro Bioscience (Suzhou) Limited
Responsible party
Sponsor
First posted
Jul 24, 2025
Start date
Jan 20, 2025
Primary completion
Apr 20, 2026
Completion
Apr 20, 2026
Last update
Oct 28, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion